Taysha Gene Therapies regains compliance with Nasdaq listing rules

Taysha Gene Therapies, Inc.

Received Nasdaq notice on Aug 28, 2023, confirming compliance with minimum Market Value of Listed Securities of $50M.
Received separate Nasdaq notice on same date confirming compliance with minimum bid price of $1.00 per share.
Both compliance matters are now closed, removing delisting risk for TSHA on Nasdaq Global Select Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.